Rigel Pharmaceuticals, Inc.
RIP1 INHIBITORY COMPOUNDS AND METHODS FOR MAKING AND USING THE SAME
Last updated:
Abstract:
Disclosed herein are kinase inhibitory compounds, such as a receptor-interacting protein-1 (RIP1) kinase inhibitor compounds, as well as pharmaceutical compositions and combinations comprising such inhibitory compounds. The disclosed compounds, pharmaceutical compositions, and/or combinations may be used to treat or prevent a kinase-associated disease or condition, particularly a RIP1-associated disease or condition.
Status:
Application
Type:
Utility
Filling date:
16 Oct 2020
Issue date:
11 Feb 2021